May 30, 2025 - 23:40

Shares of networking chip designer Marvell Technology experienced a notable decline of 6.3% during the afternoon trading session. This downturn followed the company's release of its first quarter 2025 financial results, which analysts deemed underwhelming. While sales and earnings figures were largely in line with expectations, investors were left wanting more.
The company's free cash flow margin also showed a contraction, raising concerns about its financial health moving forward. Additionally, Marvell provided full-year earnings per share guidance that was mostly in line with market forecasts, but this did little to alleviate investor apprehensions.
Overall, the quarter presented a mixed bag of results, leaving stakeholders questioning the company's growth trajectory. As the market digests this information, the decline in share price reflects a cautious sentiment among investors regarding Marvell's future performance in a competitive industry.
October 28, 2026 - 23:36
CSX Works Through Tech Outage as Security Team Confirms No CyberattackCSX is working through a technology outage that began Tuesday, with the company`s security team confirming the disruption was not a cyberattack and that no data breach occurred, according to a...
October 28, 2026 - 06:35
The Human Side of Patient CRM Upgrades: Four Choices Tech Cannot SolveModernizing a patient relationship management system is often framed as a software problem, but the hardest parts are not technical. Jaymin Sutarwala of United Therapeutics argues that four key...
October 27, 2026 - 19:33
SPOOKY SPECTACULAR - GATEWAY HEADS-UP MAFIA 2026 GRAND FINALETwo days. More than 360 cars. Nearly $30,000 in payouts. One weekend that will not be forgotten anytime soon. Some races are good. Some are memorable. Then there are weekends that remind everyone...
October 27, 2026 - 00:50
Aptar Pharma Expands Pulmonary Delivery Capabilities with Pulmotree AcquisitionAptar Pharma, a division of AptarGroup Inc., has acquired Pulmotree, a life sciences company based in Munich, Germany. The move strengthens the company`s position in pulmonary drug delivery...